In conclusion, the results of this multicenter study show that the use of R-bendamustine followed by rituximab maintenance in patients with previously untreated follicular lymphoma resulted in significantly longer PFS compared to patients treated with R-CHOP. Here, DDIT3 is linked to follicular lymphoma.